Breast Surgery

Fulvestrant breast cancer drug shows better survival than current standard, study finds


The advanced breast cancer hormone therapy ‘fulvestrant’ works better than the current standard drug treatment and reduces the risk of progression by 20%, according to a large clinical trial led by The University of Nottingham and Baylor College of Medicine in the US. 

Key data presented on Saturday 8 October 2016 at the European Society for Medical Oncology showed that the fulvestrant drug Faslodex demonstrated better survival using a 500mg dose compared to the anastrozoledrug Arimidex in the first-line treatment of postmenopausal women with locally-advanced or metastatic breast cancer. 

The FALCON trial was a Phase III, randomised, double-blind, multicentre clinical trial. It was carried out after positive results from the Phase II FIRST trial, which showed an average overall survival nearly six months longer with fulvestrant compared to anastrozole.

Click here for full story.

Posted on Monday 10th October 2016

Breast Surgery

The University of Nottingham
Royal Derby Hospital
Uttoxeter Road, Derby, DE22 3DT

telephone: +44 (0) 1332 724622